Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review

Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa

(2019) Jorge Romaní et al.   DERMATOLOGY

Ustekinumab treatment for hidradenitis suppurativa

(2019) Kana Takeda et al.   JOURNAL OF DERMATOLOGY

Hidradenitis suppurativa/acne inversa: A practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group

(2018) C.C. Zouboulis et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum

(2016) J.L. Blok et al.   BRITISH JOURNAL OF DERMATOLOGY

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study

(2015) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa

(2015) C.C. Zouboulis et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Management of Recalcitrant Hidradenitis Suppurativa with Ustekinumab

(2013) V Sharon et al.   ACTA DERMATO-VENEREOLOGICA

Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support

(2013) F.W. Danby et al.   BRITISH JOURNAL OF DERMATOLOGY

Successful long-term triple disease control by ustekinumab in a patient with Behçet's disease, psoriasis and hidradenitis suppurativa: Table 1

(2012) Ewout M Baerveldt et al.   ANNALS OF THE RHEUMATIC DISEASES

Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β

(2011) H.H. van der Zee et al.   BRITISH JOURNAL OF DERMATOLOGY

Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa

(2011) Christoph Schlapbach et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa

(2011) W.P. Gulliver et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Hidradenitis suppurativa: A comprehensive review

(2009) Ali Alikhan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET